370 related articles for article (PubMed ID: 19200869)
1. The future of multiple sclerosis treatment.
Cohen JA
J Neurol Sci; 2009 Feb; 277 Suppl 1():S55-61. PubMed ID: 19200869
[TBL] [Abstract][Full Text] [Related]
2. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
Hemmer B; Hartung HP
Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
[TBL] [Abstract][Full Text] [Related]
3. Future neuroprotective strategies.
Sättler MB; Bähr M
Exp Neurol; 2010 Sep; 225(1):40-7. PubMed ID: 19716365
[TBL] [Abstract][Full Text] [Related]
4. Translating new insights into treatment optimisation in multiple sclerosis.
Fazekas F; Kieseier BC
J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857
[No Abstract] [Full Text] [Related]
5. The pathology of MS: new insights and potential clinical applications.
Pittock SJ; Lucchinetti CF
Neurologist; 2007 Mar; 13(2):45-56. PubMed ID: 17351524
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
Aktas O; Kieseier B; Hartung HP
Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
[TBL] [Abstract][Full Text] [Related]
7. New options for early treatment of multiple sclerosis.
Tintoré M
J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
Kieseier BC; Hartung HP
Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
[No Abstract] [Full Text] [Related]
9. Linkage between immunomodulation, neuroprotection and neurogenesis.
Aharoni R; Arnon R
Drug News Perspect; 2009; 22(6):301-12. PubMed ID: 19771319
[TBL] [Abstract][Full Text] [Related]
10. The use of glatiramer acetate in the treatment of multiple sclerosis.
Wolinsky JS
Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
[TBL] [Abstract][Full Text] [Related]
11. Knowns and unknowns in the future of multiple sclerosis treatment.
Stüve O
J Neurol Sci; 2009 Dec; 287 Suppl 1():S30-6. PubMed ID: 20106346
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.
Lopez-Diego RS; Weiner HL
Nat Rev Drug Discov; 2008 Nov; 7(11):909-25. PubMed ID: 18974749
[TBL] [Abstract][Full Text] [Related]
13. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
Banwell B; Tremlett H
Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
[No Abstract] [Full Text] [Related]
14. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
Van der Walt A; Butzkueven H; Kolbe S; Marriott M; Alexandrou E; Gresle M; Egan G; Kilpatrick T
Pharmacol Ther; 2010 Apr; 126(1):82-93. PubMed ID: 20122960
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory drug treatment in multiple sclerosis.
Aharoni R
Expert Rev Neurother; 2010 Sep; 10(9):1423-36. PubMed ID: 20819013
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system infections - a potential complication of systemic immunotherapy.
Hemmer B; Frohman E; Hartung HP; Stüve O
Curr Opin Neurol; 2006 Jun; 19(3):271-6. PubMed ID: 16702834
[TBL] [Abstract][Full Text] [Related]
17. Advancement of therapies for neuroprotection in multiple sclerosis.
Lo A
Expert Rev Neurother; 2008 Sep; 8(9):1355-66. PubMed ID: 18759548
[TBL] [Abstract][Full Text] [Related]
18. Prospects of repair in multiple sclerosis.
Yong VW
J Neurol Sci; 2009 Feb; 277 Suppl 1():S16-8. PubMed ID: 19200859
[TBL] [Abstract][Full Text] [Related]
19. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
20. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
Taoufik E; Tseveleki V; Euagelidou M; Emmanouil M; Voulgari-Kokota A; Haralambous S; Probert L
Neurodegener Dis; 2008; 5(1):32-7. PubMed ID: 18075273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
